Chronic Lymphocytic Leukemia (CLL) is a lymphoproliferative disorder with either indolent or aggressive clinical course. Current treatment regiments have significantly improved the overall outcomes even if higher risk subgroups - those harboring TP53 mutations or deletions of the short arm of chromosome 17 (del17p) - remain highly challenging. In the present work, we identified USP7, a known de-ubiquitinase with multiple roles in cellular homeostasis, as a potential therapeutic target in CLL. We demonstrated that in primary CLL samples and in CLL cell lines USP7 is: i) over-expressed through a mechanism involving miR-338-3p and miR-181b deregulation; ii) functionally activated by Casein Kinase 2 (CK2), an upstream interactor known to be deregulated in CLL; iii) effectively targeted by the USP7 inhibitor P5091. Treatment of primary CLL samples and cell lines with P5091 induces cell growth arrest and apoptosis, through the restoration of PTEN nuclear pool, both in TP53-wild type and -null environment. Importantly, PTEN acts as the main tumor suppressive mediator along the USP7-PTEN axis in a p53 dispensable manner. In conclusion, we propose USP7 as a new druggable target in CLL.

Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones

CARRA', GIOVANNA;PANUZZO, Cristina;TORTI, DAVIDE;CRIVELLARO, SABRINA;Volante, Marco;MORENA, DEBORAH;LINGUA, MARCELLO FRANCESCO;BRANCACCIO, Mara;GUERRASIO, Angelo;PANDOLFI DE RINALDIS, Pier Paolo;SAGLIO, Giuseppe;TAULLI, Riccardo
;
MOROTTI, Alessandro
Last
2017

Abstract

Chronic Lymphocytic Leukemia (CLL) is a lymphoproliferative disorder with either indolent or aggressive clinical course. Current treatment regiments have significantly improved the overall outcomes even if higher risk subgroups - those harboring TP53 mutations or deletions of the short arm of chromosome 17 (del17p) - remain highly challenging. In the present work, we identified USP7, a known de-ubiquitinase with multiple roles in cellular homeostasis, as a potential therapeutic target in CLL. We demonstrated that in primary CLL samples and in CLL cell lines USP7 is: i) over-expressed through a mechanism involving miR-338-3p and miR-181b deregulation; ii) functionally activated by Casein Kinase 2 (CK2), an upstream interactor known to be deregulated in CLL; iii) effectively targeted by the USP7 inhibitor P5091. Treatment of primary CLL samples and cell lines with P5091 induces cell growth arrest and apoptosis, through the restoration of PTEN nuclear pool, both in TP53-wild type and -null environment. Importantly, PTEN acts as the main tumor suppressive mediator along the USP7-PTEN axis in a p53 dispensable manner. In conclusion, we propose USP7 as a new druggable target in CLL.
8
22
35508
35522
PTEN; USP7; chronic lymphocytic leukemia; miR181; miR338
Carrà, Giovanna; Panuzzo, Cristina; Torti, Davide; Parvis, Guido; Crivellaro, Sabrina; Familiari, Ubaldo; Volante, Marco; Morena, Deborah; Lingua, Marcello Francesco; Brancaccio, Mara; Guerrasio, Angelo; Pandolfi, Pier Paolo; Saglio, Giuseppe; Taulli, Riccardo; Morotti, Alessandro
File in questo prodotto:
File Dimensione Formato  
Guerrasio_1_Therapeutic inhibition.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 2.36 MB
Formato Adobe PDF
2.36 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1635932
Citazioni
  • ???jsp.display-item.citation.pmc??? 35
  • Scopus 48
  • ???jsp.display-item.citation.isi??? 44
social impact